Immunogenicity of three sequential schedules with Sabin inactivated poliovirus vaccine and bivalent oral poliovirus vaccine in Zhejiang, China: an open-label, randomised, controlled trial
- PMID: 32442523
- DOI: 10.1016/S1473-3099(19)30738-8
Immunogenicity of three sequential schedules with Sabin inactivated poliovirus vaccine and bivalent oral poliovirus vaccine in Zhejiang, China: an open-label, randomised, controlled trial
Abstract
Background: The globally synchronised introduction of inactivated poliovirus vaccine (IPV) and replacement of trivalent oral poliovirus vaccine (OPV) with bivalent OPV (bOPV) were successfully implemented in China's routine immunisation programme in May, 2016. In response to the global shortage of Salk-strain IPV, Sabin-strain IPV production was encouraged to develop and use in low-income and middle-income countries. We assessed the immunogenicity of the current routine poliovirus vaccination schedule in China and compared it with alternative schedules that use Sabin-strain IPV (sIPV) and bOPV.
Methods: This open-label, randomised, controlled trial recruited healthy infants aged 60-75 days from two centres in Zhejiang, China. Eligible infants were full-term, due for their first polio vaccination, weighed more than 2·5 kg at birth, were healthy on physical examination with no obvious medical conditions, and had no contraindications to vaccination. Infants were randomly assigned (1:1:1) using permuted block randomisation (block size of 12) to one of three polio vaccination schedules, with the first, second, and third doses given at ages 2 months, 3 months, and 4 months, respectively: sIPV-bOPV-bOPV (1sIPV+2bOPV group; current regimen), sIPV-sIPV-bOPV (2sIPV+1bOPV group), or sIPV-sIPV-sIPV (3sIPV group). The primary endpoint was the proportion of infants with seroconversion to each of the three poliovirus serotypes 1 month after the third dose. Serious and medically important adverse events were monitored for up to 30 days after each vaccination. We assessed immunity in the per-protocol population (all children who completed all three vaccinations and had pre-vaccination and post-vaccination laboratory data) and safety in all children who received at least one dose of study vaccine. This trial is registered with Clinicaltrials.gov, NCT03147560.
Results: Between May 1, 2016, and Dec 1, 2017, we enrolled and randomly assigned 528 eligible infants to one of the three treatment groups (176 in each group); 473 infants (158 in the 1sIPV+2bOPV group, 152 in the 2sIPV+1bOPV group, and 163 in the 3sIPV group) were included in the per-protocol population. 100% seroconversion against poliovirus types 1 and 3 was observed in all three groups. Infants who received an immunisation schedule containing bOPV had significantly higher antibody titres against poliovirus types 1 and 3 than did the sIPV-only group (2048 in all three treatment groups; p<0·0001). Seroconversion against type 2 poliovirus was observed in 98 (62%) infants in the 1sIPV+2bOPV group, 145 (95%) infants in the 2sIPV+1bOPV group, and 161 (99%) infants in the 3sIPV group. No serious adverse events occurred during the study; 14 minor, transient adverse events were observed, with no significant differences across study groups.
Interpretation: All three study schedules were well tolerated and highly immunogenic against poliovirus types 1 and 3. Schedules containing two or three sIPV doses had higher seroconversion rates against poliovirus type 2 than did the schedule with a single dose of sIPV. Our findings support inclusion of two sIPV doses in the routine poliovirus vaccination schedule in China to provide better protection against poliovirus type 2 than provided by the current regimen.
Funding: Chinese Center for Disease Control and Prevention and China National Biotec Group Company.
Copyright © 2020 Elsevier Ltd. All rights reserved.
Comment in
-
Sequential inactivated and oral poliovirus vaccine schedules: a balancing act.Lancet Infect Dis. 2020 Sep;20(9):999-1000. doi: 10.1016/S1473-3099(20)30083-9. Epub 2020 May 19. Lancet Infect Dis. 2020. PMID: 32442524 Free PMC article. No abstract available.
Similar articles
-
[Comparing the immunogenicity and safety of sequential inoculation of sIPV followed by bOPV (Ⅰ+Ⅲ) in different dosage forms].Zhonghua Yu Fang Yi Xue Za Zhi. 2018 Jan 6;52(1):43-49. doi: 10.3760/cma.j.issn.0253-9624.2018.01.009. Zhonghua Yu Fang Yi Xue Za Zhi. 2018. PMID: 29334707 Chinese.
-
Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study.Lancet Infect Dis. 2015 Nov;15(11):1273-82. doi: 10.1016/S1473-3099(15)00219-4. Epub 2015 Aug 26. Lancet Infect Dis. 2015. PMID: 26318714 Clinical Trial.
-
Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial.Lancet. 2016 Jul 9;388(10040):158-69. doi: 10.1016/S0140-6736(16)00703-0. Epub 2016 May 19. Lancet. 2016. PMID: 27212429 Clinical Trial.
-
Immunogenicity to poliovirus type 2 following two doses of fractional intradermal inactivated poliovirus vaccine: A novel dose sparing immunization schedule.Vaccine. 2017 May 19;35(22):2993-2998. doi: 10.1016/j.vaccine.2017.03.008. Epub 2017 Apr 20. Vaccine. 2017. PMID: 28434691 Free PMC article. Review.
-
Immunogenicity of New Primary Immunization Schedules With Inactivated Poliovirus Vaccine and Bivalent Oral Polio Vaccine for the Polio Endgame: A Review.Clin Infect Dis. 2018 Oct 30;67(suppl_1):S35-S41. doi: 10.1093/cid/ciy633. Clin Infect Dis. 2018. PMID: 30376081 Free PMC article. Review.
Cited by
-
Immuno-persistence of the different primary polio vaccine schedules and immunogenicity of the booster dose by sabin inactivated or bivalent oral poliovirus vaccine in children aged 4 years: an open-label, randomised, controlled phase 4 trial in China.Lancet Reg Health West Pac. 2023 Mar 17;34:100725. doi: 10.1016/j.lanwpc.2023.100725. eCollection 2023 May. Lancet Reg Health West Pac. 2023. PMID: 37283972 Free PMC article.
-
Evaluation of the immunization effectiveness of bOPV booster immunization and IPV revaccination.NPJ Vaccines. 2023 Mar 18;8(1):44. doi: 10.1038/s41541-023-00642-w. NPJ Vaccines. 2023. PMID: 36934085 Free PMC article.
-
Long-Term Immunogenicity of Inactivated and Oral Polio Vaccines: An Italian Retrospective Cohort Study.Vaccines (Basel). 2022 Aug 17;10(8):1329. doi: 10.3390/vaccines10081329. Vaccines (Basel). 2022. PMID: 36016217 Free PMC article.
-
Safety evaluation on concomitant immunization with inactivated poliomyelitis vaccine produced from Sabin strains and other vaccines (from 2015 to 2020).Hum Vaccin Immunother. 2022 Dec 31;18(1):2041944. doi: 10.1080/21645515.2022.2041944. Epub 2022 Mar 8. Hum Vaccin Immunother. 2022. PMID: 35258415 Free PMC article.
-
Immunogenicity of two-dose and three-dose vaccination schedules with Sabin inactivated poliovirus vaccine in China: An open-label, randomized, controlled trial.Lancet Reg Health West Pac. 2021 Apr 16;10:100133. doi: 10.1016/j.lanwpc.2021.100133. eCollection 2021 May. Lancet Reg Health West Pac. 2021. PMID: 34327346 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical
Research Materials